Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 5/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.59 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278130 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL24299397 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL16114092 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL19938159 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL13833323 | 1.00 | HINT1 (0.62) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL27221934 | 0.99 | HINT1 (0.61) | HINT1ADORA3NT5ESTING1PDE3B | |
| Phosphoric Acid SCHEMBL1299515 | 0.96 | NT5E (0.63) | HINT1ADORA3NT5ESTING1PDE3B | |
| Phosphoric Acid SCHEMBL25402859 | 0.96 | NT5E (0.63) | HINT1ADORA3NT5ESTING1PDE3B | |
| SCHEMBL21232923 | 0.92 | HINT1 (0.56) | HINT1ADORA3NT5ESTING1PDE3B | |
| Phosphoric Acid SCHEMBL17505120 | 0.92 | NT5E (0.61) | HINT1ADORA3NT5ESTING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638898-A | Method for targeted nucleic acid sequence enrichment and use in error-correcting nucleic acid sequencing | 华盛顿大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-110520542-B | Method for targeted nucleic acid sequence enrichment and use in error-correcting nucleic acid sequencing | 华盛顿大学 | 2024-06-14 | — | — | CN | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| EP-3027754-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | enEvolv, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017866-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2014160200-A9 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-11-27 | — | — | WO | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| WO-2014160200-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20130028920-A1 | STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF | UNIVERSITE DE GENEVE (CH) | 2013-01-31 | — | — | US | disclosed |
| US-20130017197-A1 | STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF | UNIVERSITE DE GENEVE (CH) | 2013-01-17 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090118140-A1 | METHOD AND SYSTEM FOR ASSEMBLY OF MACROMOLECULES AND NANOSTRUCTURES | XF TECHNOLOGIES INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008112980-A2 | METHOD AND SYSTEM FOR ASSEMBLY OF MACROMOLECULES AND NANOSTRUCTURES | INCITOR, LLC (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017197-A1 | STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF | FCGRT, IGLV6-57, FCGR3B | HINT1 2950/4885ADORA3 2620/4885NT5E 955/4885 |
| US-20130028920-A1 | STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF | FCGRT, IGLV6-57, FCGR3B | HINT1 2950/4885ADORA3 2620/4885NT5E 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.